治療用組換え抗体・タンパク質の世界市場：規模、シェア、動向、予測（2022年～2028年）

世界の治療用組換え抗体・タンパク質の市場規模は、抗体ベースの治療薬の開発、哺乳類発現系・微生物発現系の発展などによって促進されています。

当レポートでは、世界の治療用組換え抗体・タンパク質市場を調査しており、市場の概要、市場規模や予測、動向、成長要因、抑制要因、医薬品クラス・用途・地域別の分析、および競合情勢などを提供しています。

目次

第1章 調査目的・前提条件

• 調査目的
• 仮定
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
  • 市場内訳：医薬品クラス別
  • 市場内訳：用途別
  • 市場内訳：地域別
• コヒーレントオポチュニティマップ（COM）

第3章 市場力学、規制、および動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 市場動向
• パイプライン分析
• 医薬品開発の課題
• 新規市場参入者
• 規制シナリオ
• PEST分析
• ポーターの分析

第4章 世界の治療用組換え抗体・タンパク質市場：医薬品クラス別（2017年～2028年）

• イントロダクション
• 血漿タンパク質
• 成長因子
• 融合タンパク質
• モノクローナル抗体
• ホルモン
• 酵素
• 凝固因子
• その他

第5章 世界の治療用組換え抗体・タンパク質市場：用途別（2017年～2028年）

• イントロダクション
• 腫瘍学
• 血液学
• 免疫学
• 内分泌学
• 感染症
• 循環器疾患
• その他

第6章 世界の治療用組換え抗体・タンパク質市場：地域別（2017年～2028年）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第7章 競合情勢

• ヒートマップ分析
• 企業プロファイル
  • Abbott*
  • Amgen Inc.
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Johnson and Johnson
  • Merck &Co.
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi SA
• アナリストの見解

第8章 セクション

Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies are highly successful and experience unparalleled growth potential in terms of their efficacy.

Market Dynamics

Recombinant therapeutic proteins and antibodies have gained high traction in clinical applications. Due to development of antibody-based therapeutics, mammalian expression systems have experienced a major boost and microbial expression systems continue to be widely used in industries, which in turn will fuel growth of the market. However, variations in production methods of therapeutic antibodies can lead to differences in their structure, based on the selection of recombinant procedure. Most protein therapeutics available in the market are recombinant and majority of them are in clinical trials for therapy of immune disorders, cancers, infections, and other diseases. Various engineered proteins, including multi-specific fusion proteins, bi-specific monoclonal antibodies (mAbs) and mAbs conjugated small molecule drugs, and proteins with optimized pharmacokinetics are under development.

Key features of the study:

This report provides in-depth analysis of recombinant therapeutic antibodies and proteins market and provides market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global recombinant therapeutic antibodies and proteins market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans

Key companies covered as a part of this study include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global recombinant therapeutic antibodies and proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the recombinant therapeutic antibodies and proteins market

Detailed Segmentation:

Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Geography:

North America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

U.S.

Canada

Latin America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

GCC

Israel

Rest of Middle East

Africa Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

North Africa

South Africa

Central Africa

Company Profiles

Abbott Laboratories*

Company Overview

Product Portfolio

Key Highlights

Financial Overview

Market Strategy

Amgen Inc.

Biogen Inc.

Eli Lilly and Company

F. Hoffmann-La Roche

Johnson and Johnson

Merck & Co.

Novo Nordisk

Pfizer, Inc.

Sanofi S.A.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Application
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Pipeline Analysis
• Drug Development Challenges
• New Market Entrants
• Regulatory Scenario
• PEST Analysis
• Porter's Analysis

4. Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Plasma Protein
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Growth Factors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Fusion Proteins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Monoclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Hormones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Enzyme
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Coagulation Factors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Recombinant Therapeutic Antibodies and Proteins Market, Application, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Hematology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Immunology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Endocrinology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Infectious Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Cardiovascular Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Recombinant Therapeutic Antibodies and Proteins Market, By Region, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • Regional Trends
• North America
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • U.S.
  • Canada
• Latin America
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • South Africa
  • Central Africa
  • North Africa

7. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Abbott*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Amgen Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Biogen Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Eli Lilly and Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • F. Hoffmann-La Roche
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Johnson and Johnson
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Merck & Co.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Novo Nordisk
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Pfizer Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Sanofi S.A.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
• Analyst Views

8. Section

• References
• Research Methodology
• About us and Sales Contact